{Reference Type}: Journal Article {Title}: Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice. {Author}: Ståhle M;Silvola JMU;Hellberg S;de Vries M;Quax PHA;Kroon J;Rinne P;de Jong A;Liljenbäck H;Savisto N;Wickman A;Stroes ESG;Ylä-Herttuala S;Saukko P;Abrahamsson T;Pettersson K;Knuuti J;Roivainen A;Saraste A; {Journal}: JACC Basic Transl Sci {Volume}: 5 {Issue}: 4 {Year}: Apr 2020 {Factor}: 9.531 {DOI}: 10.1016/j.jacbts.2020.01.008 {Abstract}: This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.